| Market Cap | 26.71M |
| Revenue (ttm) | 29.91M |
| Net Income (ttm) | -5.20M |
| Shares Out | n/a |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 399,154 |
| Average Volume | 96,909 |
| Open | 0.0620 |
| Previous Close | 0.0700 |
| Day's Range | 0.0612 - 0.0683 |
| 52-Week Range | 0.0370 - 0.0850 |
| Beta | 0.32 |
| RSI | 50.50 |
| Earnings Date | May 15, 2025 |
About MediPharm Labs
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, develops, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll canna... [Read more]
Full Company ProfileFinancial Performance
In 2024, MediPharm Labs's revenue was 41.96 million, an increase of 26.92% compared to the previous year's 33.06 million. Losses were -10.69 million, -18.26% less than in 2023.
Financial numbers in CAD Financial StatementsNews
Apollo Capital Warns MediPharm Shareholders of Continued Value Destruction and Insolvency Risk Following Disastrous Q1 Financial Results
MediPharm is Dangerously Low On Cash and is On Track to Run Out of Money by November Unless Wholesale Change Occurs MediPharm Lost Over $3.3 Million in Q1 2025 While Management Offered No Clear Plan t...
MediPharm Labs Raises Concerns About Poorly Qualified Dissident Nominees
TORONTO , May 15, 2025 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today provided its sharehol...
MediPharm Labs Corp. (MEDIF) Q1 2025 Earnings Call Transcript
MediPharm Labs Corp. (MEDIF Q1 2025 Earnings Conference Call May 14, 2025 10:00 AM ET Company Participants David Pidduck - President & Chief Executive Officer Greg Hunter - Chief Financial Officer Con...
Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders
Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders $1 Billion Conferenc...
MediPharm Labs Announces Strong Q1 2025 Results
Achieves Positive Adjusted EBITDA(1) Revenue of $10.8 Million, an Increase of 11% over Q1 2024 87% Growth in International Medical Cannabis Revenue, Forming 55% of Total Revenue Gross Profit of $4.2 m...
MediPharm Labs Sets Date to Report First Quarter 2025 Financial Results
TORONTO , May 9, 2025 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based...
MediPharm Labs Responds to Dissident Shareholder's Filing
TORONTO , May 8, 2025 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is aware of the dissident pr...
Apollo Technology Capital Corporation to Nominate Six Highly Qualified Directors to MediPharm Labs' Board of Directors Following Years of Shareholder Value Destruction
Believes Board Change is Urgently Needed: Under the Current Board and Management, MediPharm Stock Price is Down More Than 99%, Costing Shareholders Nearly $1 Billion MediPharm's Board Cannot be Truste...
MediPharm Labs Reports Full Year & Fourth Quarter 2024 Results
Annual Net Revenue Increase of 27% to $42M, Driven by Record $18M International Medical Cannabis Revenue and Approaching Positive Adjusted EBITDA(1) for Q4. TORONTO , March 31, 2025 /PRNewswire/ - Med...
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2024 Financial Results
TORONTO , March 26, 2025 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-ba...
MediPharm Labs Announces Termination of the Proposed Sale of Napanee Facility to Kensana Health
TORONTO , Feb. 10, 2025 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) ("MediPharm", "MediPharm Labs" or the "Company") has terminated the previously announced sale of its facility in ...
MediPharm Labs Provides Update on Previously Announced Sale of Napanee Facility to Kensana Health
TORONTO , Jan. 16, 2025 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) ("MediPharm", "MediPharm Labs" or the "Company") is pleased to provide an update with respect to the previously a...
MediPharm Labs Enters Landmark Commercial Agreement with Laboratório Teuto in Brazil
MediPharm Labs expands its Brazilian presence where the medical cannabis market is estimated to be worth $198 million in 2024, serving over 670,000 patients.1 Products include full-spectrum, GMP subli...
MediPharm Labs to Sell its Napanee Facility to Kensana Health for $5.5M
TORONTO , Dec. 17, 2024 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) ("MediPharm", "MediPharm Labs" or the "Company") and Kensana Health Inc. ("Kensana Health") are pleased to announ...
MediPharm Labs Reports Third Quarter Results
Strong Growth in International GMP Medical Markets TORONTO , Nov. 14, 2024 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a ...
MediPharm Labs Sets Date to Report Third Quarter 2024 Financial Results
TORONTO , Nov. 11, 2024 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-bas...
MediPharm Labs Announces Departure of President and Co-Founder Keith Strachan
TORONTO , Oct. 17, 2024 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) ("MediPharm", "MediPharm Labs" or the "Company"), a specialized, research-driven company focused on pharmaceutica...
MediPharm Labs Announces $2.1M Debt Repayment
Company Now Materially Debt Free with Over $13M in Cash TORONTO , Sept. 17, 2024 /PRNewswire/ - MediPharm Labs Corp. ("MediPharm" or the "Company") (TSX: LABS), a specialized, research-driven pharmace...
MediPharm Labs Corp. (MEDIF) Q2 2024 Earnings Call Transcript
MediPharm Labs Corp. (OTCQB:MEDIF) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants David Pidduck - Chief Executive Officer Keith Strachan - President Greg Hunter - Chi...
MediPharm Labs Reports Second Quarter Results Closing in on Positive Adjusted EBITDA(1) as Gross Profit Continues to Improve
TORONTO , Aug. 14, 2024 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-bas...
/R E P E A T -- MediPharm Labs Sets Date to Report Second Quarter 2024 Financial Results/
TORONTO , Aug. 8, 2024 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-base...
MediPharm Labs Sets Date to Report Second Quarter 2024 Financial Results
TORONTO , Aug. 8, 2024 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-base...
MediPharm Labs Announces Voting Results From the 2024 Annual Meeting of Shareholders
TORONTO , June 26, 2024 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-ba...
MediPharm Labs Acquires Advanced Medical Cannabis Delivery Method Technology from Remidose Aerosols
MediPharm has licenced global manufacturing, distribution, and sales rights of the novel advanced medical cannabis technology from Remidose Aerosols. Products include metered dose inhalers and aeroso...
MediPharm Labs Corp. (MEDIF) Q1 2024 Earnings Call Transcript
MediPharm Labs Corp. (OTCQB:MEDIF) Q1 2024 Earnings Conference Call May 15, 2024 8:30 AM ET Company Participants David Pidduck - CEO Keith Strachan - President Greg Hunter - CFO Conference Call Partic...